High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The platform collects and sequences biospecimens (blood, tissue, urine, saliva, and surgical drainage) and links those molecular results to imaging and clinical data to detect minimal/molecular residual disease (MRD). Clinical annotation captures patient and disease characteristics, treatments, and outcomes to contextualize ctDNA findings. Patients who are MRD positive may be referred to separate interception treatment trials, while serial blood and imaging are used to monitor MRD clearance and correlate with relapse. Exploratory correlative analyses aim to improve sensitivity and interpretation of ctDNA-based MRD across multiple tumor types.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.
2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant/maintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.
3. Patient must be ≥ 18 years old.
4. All patients must have signed and dated an informed consent form.

Exclusion Criteria:

1\. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.

Where it's running

• Princess Margaret Hospital
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Lillian Siu, MD — Princess Margaret Cancer Centre
• Study coordinator: Kimberly Vuong
• Email: Gilgan.Centre@uhn.ca
• Phone: 437-676-6598

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collecting tumor samples to improve cancer treatment matching

  This study is collecting tumor samples from patients with advanced cancer to see if analyzing their genes can help doctors find the best treatments for them.

  Recruiting at 2 sites University Health Network, Toronto · Hamilton, Ontario and 6 other locations · NCT02906943

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Using blood tests to assess early treatment response in cancer patients

  This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04354064

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.